Posted by Michael Wonder on 21 Feb 2023
Icosavax granted FDA fast track designation for IVX-A12
21 February 2023 - Icosavax today announced the US FDA has granted fast track designation for IVX-A12, a bivalent respiratory syncytial virus and human metapneumovirus VLP vaccine candidate, in older adults 60 years of age and above.
In October 2022, Icosavax announced the initiation of a Phase 1, randomised, observer-blinded, placebo-controlled, multi-centre study of IVX-A12, with and without CSL Seqirus’ proprietary adjuvant MF59, in up to 120 healthy older adults aged 60 to 75 years.
